6 Drug Makers to Participate in “Drug Redirection Program” for Compounds in Development Limbo: Univ. of Tokyo’s Initiative

The University of Tokyo recently announced that six drug makers will participate in its “drug redirection program,” a program through which compounds whose development was suspended by drug makers at the clinical trial stage will be introduced to university researchers...read more